Sarcoma care in the era of precision medicine

Article Pathology

Primary Pulmonary Myxoid Sarcoma with EWSR1::ATF1 Fusion: A Case Report

Tomoki Nishimura et al.

Summary: Primary pulmonary myxoid sarcoma is a rare lung sarcoma that requires pathological findings and gene rearrangements for accurate diagnosis.

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2023)

Add to Collection

Article Oncology

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Mrinal M. M. Gounder et al.

Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, an MDM2 inhibitor, in patients with advanced cancers. The study found that an intermittent dosing schedule of milademetan can mitigate dose-limiting hematologic abnormalities while maintaining efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex

Jialin Mo et al.

Summary: The study identifies SSRP1 as a crucial gene that is directly induced by EWSR1::FLI1 and forms an oncogenic positive feedback loop with it, promoting EwS oncogenesis. The FACT inhibitor CBL0137 effectively disrupts this loop, providing a novel therapeutic strategy for treating EwS.

ONCOGENE (2023)

Add to Collection

Article Multidisciplinary Sciences

Heritable defects in telomere and mitotic function selectively predispose to sarcomas

Mandy L. Ballinger et al.

Summary: Cancer genetics has focused on epithelial malignancies, but this study explores specific pathways related to sarcomas, rare malignancies derived from embryonic mesoderm. Germline sequencing of sporadic cases and healthy controls reveals two sarcoma-specific pathways involved in mitotic and telomere functions. Centrosome gene variants are linked to specific tumors, while heritable defects in the shelterin complex increase susceptibility to sarcomas, melanomas, and thyroid cancers. These findings highlight the role of heritable defects in mitotic and telomere biology in sarcoma risk.

SCIENCE (2023)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Soft-tissue sarcoma in adults: Imaging appearances, pitfalls and diagnostic algorithms

Amandine Crombe et al.

Summary: This article provides an overview of diagnostic imaging for soft-tissue sarcomas. It includes a diagnostic flow-chart based on initial radiological findings and emphasizes the role of sarcoma reference centers and radiologists. It also discusses imaging-guided biopsies and methods for improving soft-tissue sarcoma grading with imaging.

DIAGNOSTIC AND INTERVENTIONAL IMAGING (2023)

Add to Collection

Article Economics

Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer

Martijn J. H. G. Simons et al.

Summary: This study aimed to investigate the cost-effectiveness, budget impact, and impact of uncertainty of future developments concerning whole-genome sequencing (WGS) as a clinical diagnostic test compared with standard of care in patients with non-small cell lung cancer. The findings suggest that WGS is likely to become cost-effective in the near future if it identifies more patients with actionable targets and shows the impact of uncertainty regarding its diagnostic yield.

VALUE IN HEALTH (2023)

Add to Collection

Article Oncology

Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS

Patrick Schoffski et al.

Summary: This article describes an ongoing clinical trial evaluating the efficacy of BI 907828 versus doxorubicin as first-line treatment for advanced DDLPS. The study shows that BI 907828 is able to inhibit the growth of DDLPS and has better efficacy compared to the chemotherapy drug doxorubicin.

FUTURE ONCOLOGY (2023)

Add to Collection

Article Oncology

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib

C. Serrano et al.

Summary: This study used ctDNA sequencing to analyze the impact of KIT/PDGFRA gene mutations on TKI resistance and evaluate its clinical validity and utility. The results showed that ctDNA sequencing can efficiently detect KIT/PDGFRA mutations and predict the treatment response of GIST patients to avapritinib.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Article Oncology

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care

Andrea Vingiani et al.

JCO Precision Oncology (2023)

Add to Collection

Review Oncology

Staging Systems and Nomograms for Soft Tissue Sarcoma

Maria Danieli et al.

Summary: Reliable tools for prognosis prediction are crucially needed by oncologists to tailor individual treatments for sarcoma patients. Nomograms, which incorporate multiple risk factors and return a numerical probability of clinical events, could better account for the granularity of sarcomas compared to the widely used TNM staging system. New dynamic nomograms and prognostic tools have been developed, allowing doctors to recalculate prognosis based on time since primary surgery, event history, and the potential time-dependent effect of covariates. This review provides an overview of available nomograms for sarcomas to assist clinicians in selecting the most suitable tool for each patient.

CURRENT ONCOLOGY (2023)

Add to Collection

Review Oncology

Advances in sarcoma molecular diagnostics

Xue Qi Wang et al.

Summary: Sarcomas are malignant tumors of mesenchymal origin that require ancillary testing for accurate classification. Recent technological advances have led to the development of more comprehensive and high-throughput assays, replacing the need for traditional single gene tests. These new methods include next-generation sequencing, fluorescent bar code hybridization, and DNA methylation profiling.

GENES CHROMOSOMES & CANCER (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations

Anna Vaynrub et al.

Summary: This article reviews the treatment modalities for TGCT, introduces a new drug called pexidartinib for TGCT, and compares its efficacy and safety profile with surgery, radiotherapy, and watchful monitoring. The results show that pexidartinib has shown promising outcomes in improving joint mobility, pain, and recurrence-free survival.

ONCOTARGETS AND THERAPY (2022)

Add to Collection

Article Oncology

Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients

Luuk J. Schipper et al.

Summary: Whole genome sequencing (WGS) can uncover potential diagnostic and actionable genomic characteristics in sarcoma patients that are often overlooked, providing valuable information for clinical decision making.

CANCERS (2022)

Add to Collection

Article Oncology

Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies

Tun Kiat Ko et al.

Summary: Liquid biopsy ctDNA-based approaches provide a non-invasive means for molecular interrogation of GISTs, particularly during disease progression.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis

Nicolas Penel et al.

Summary: This prospective nationwide cohort study aimed to investigate the outcomes of desmoid-type fibromatosis (DF), focusing on the prognostic value of CTNNB1 mutations. The results showed that CTNNB1 mutation profile was associated with unfavorable prognostic factors but was not a prognostic factor for event-free survival (EFS).

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Medicine, Research & Experimental

The diagnostic utility of DNA copy number analysis of core needle biopsies from soft tissue and bone tumors

Jan Koster et al.

Summary: Morphologic and immunohistochemical analysis of preoperative core needle biopsies is crucial for the management of soft tissue and bone tumors. The use of single nucleotide polymorphism array analysis can provide diagnostic information about copy number aberrations.

LABORATORY INVESTIGATION (2022)

Add to Collection

Review Oncology

Risk Factors for Occurrence and Relapse of Soft Tissue Sarcoma

Pia Weskamp et al.

Summary: This systematic review and meta-analysis identified risk factors and prognostic indicators for the development and recurrence of soft tissue sarcomas (STS). Results showed that smoking, genetic predisposition, chronic inflammation, and toxins were associated with the development of STS, while margin of resection, chemotherapy, and radiation were associated with a higher risk of relapse.

CANCERS (2022)

Add to Collection

Article Oncology

Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice

Kris G. Samsom et al.

Summary: This study aimed to evaluate the feasibility and efficacy of whole-genome sequencing (WGS) in routine clinical practice. The results showed that WGS can be successfully applied to patients with metastatic cancer, providing comprehensive genomic profiling for the majority of patients and identifying actionable biomarkers and treatment options.

JOURNAL OF PATHOLOGY (2022)

Add to Collection

Article Oncology

Soft Tissue Sarcoma, Version 2.2022

Margaret von Mehren et al.

Summary: Soft tissue sarcomas (STS) are rare malignancies with diverse clinical and pathological characteristics. The diagnosis and treatment of STS require a multidisciplinary team. The NCCN Clinical Practice Guidelines provide comprehensive recommendations for the management of STS, including diagnosis, evaluation, and treatment.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Multidisciplinary Sciences

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Mrinal M. Gounder et al.

Summary: This study provides a comprehensive molecular analysis of sarcomas using targeted panel sequencing, identifying recurrent alterations and potential therapeutic targets. The findings shed light on the genetic landscape of sarcomas and may contribute to the development of precision-based therapies and improved clinical outcomes for patients with these rare cancers.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Multidisciplinary Sciences

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Benjamin A. Nacev et al.

Summary: Sarcomas are rare tumors with diverse genetic features and clinical outcomes. This study analyzes over 2000 sarcomas across 45 subtypes and identifies distinct genomic groups that differ from histological subgroups. The complex genetic heterogeneity of sarcomas makes it challenging to identify therapeutic targets and advance patient care. The findings of this study provide valuable insights into subtype-specific genetic alterations and will contribute to the improvement of sarcoma models and further investigations of genetic factors and treatment responses.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Multidisciplinary Sciences

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

Angela Martinez-Monleon et al.

Summary: In neuroblastoma, amplification of 12q loci, particularly CDK4 and MDM2, is common and can be targeted for inhibition to reduce cell proliferation, especially in p53(wild-type) cells. The combination of CDK4/MDM2 inhibition has an additive effect in p53(wild-type) cell lines but not p53(mutated) cells. This aggressive neuroblastoma subgroup with 12q amplification and atypical clinical presentation may benefit from CDK4 and/or MDM2 inhibition according to in vitro studies.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Pediatrics

Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents

Markus G. Seidel et al.

Summary: Detecting ctDNA in pediatric Ewing sarcoma using ddPCR is a feasible method for monitoring MRD activity in real time. While there is high variability between patients, changes in ctDNA levels correlate well with clinical outcomes within patients.

FRONTIERS IN PEDIATRICS (2022)

Add to Collection

Article Oncology

A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective Study

Xianbiao Xie et al.

Summary: This study aimed to investigate the mutational characterization and potential biomarkers of bone tumors. Through genetic testing, common mutated genes and amplification of genes were identified, with differences found between patients of different ages. The genomic alterations corrected the diagnosis of some bone tumors and identified some commonly misdiagnosed bone tumors. Additionally, RNA sequencing technology effectively increased the detection rate of gene fusions, providing assistance in the diagnosis of bone tumors.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Timothy M. Caldwell et al.

Summary: Based on knowledge of kinase switch-control inhibition, a novel series of dihydropyrimidone-based CSF1R kinase inhibitors were identified using structure-based drug design and standard medicinal chemistry principles. These inhibitors displayed high selectivity for CSF1R over a wide range of kinases and non-kinase protein targets. Compound 20 (vimseltinib) emerged as a lead candidate for clinical evaluation in the treatment of Tenosynovial Giant Cell Tumor (TGCT).

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)

Add to Collection

Article Oncology

Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour

Tatiana Georgiesh et al.

Summary: This study validated the G-score model in a large international cohort with long-term follow-up and demonstrated its superior accuracy in predicting early and late recurrence risk in solitary fibrous tumours (SFTs) compared to other models. A less intensive follow-up schedule could be considered for low-risk patients according to the G-score.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial

Bernadette Brennan et al.

LANCET (2022)

Add to Collection

Article Oncology

Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial

Richard D. Neal et al.

Summary: NHS-Galleri is a trial that aims to assess the effectiveness of a blood test in early cancer detection. It has enrolled over 140,000 participants from England and will determine the clinical utility of population screening with the test.

CANCERS (2022)

Add to Collection

Article Oncology

Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care

Edwin Cuppen et al.

Summary: The combination of whole-genome and transcriptome sequencing (WGTS) is a comprehensive precision diagnostic test that is expected to transform diagnosis and treatment for cancer patients. However, there are barriers to the implementation and widespread adoption of this test, including considerations of utility in different cancer types, cost-effectiveness and affordability.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Review Oncology

Impact of tissue-agnostic approvals for patients with sarcoma

Roberto Carmagnani Pestana et al.

Summary: Tissue-agnostic drug development provides new treatment options for rare tumors, but challenges remain due to heterogeneous nature and failed clinical trials in sarcomas. Approvals for neurotrophic tyrosine receptor kinase (NTRK) fusion, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) phenotype, and tumor mutation burden-high (TMB-H) status are particularly important in sarcomas. Future research may focus on tissue-agnostic targets such as rearranged during transfection (RET), fibroblast growth factor receptor (FGFR), and neuregulin-1 (NRG1).

TRENDS IN CANCER (2022)

Add to Collection

Article Surgery

The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only A Meta-analysis of Individual Patient Data

Milea J. M. Timbergen et al.

Summary: This study found that patients with primary sporadic DTFs harboring a CTNNB1 S45F mutation have a higher risk of recurrence after surgery, with this association being mediated by tumor size.

ANNALS OF SURGERY (2021)

Add to Collection

Article Oncology

Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

He Li et al.

Summary: Exome sequencing revealed that 7.3% of RMS patients carried cancer predisposition gene variants, mainly in predisposition syndrome genes. The distribution of germline variants differed by histology, with 40.0% of variants identified in patients older than 3 years of age.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Oncology

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

Robin L. Jones et al.

Summary: The study showed that targeting PDGFRA D842V-mutant GIST with avapritinib resulted in unprecedented, durable clinical benefit and manageable safety profile, suggesting avapritinib may be considered as first-line therapy for these patients.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Multidisciplinary Sciences

Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network

Gonzague de Pinieux et al.

Summary: The nationwide registry of sarcoma in France reveals a higher incidence of sarcoma and TIM than previously reported, with tumors with very low incidence being less likely to participate in clinical trials. The study also highlights the importance of comprehensive histological review in understanding sarcoma incidence and clinical trial participation.

PLOS ONE (2021)

Add to Collection

Article Oncology

STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma

Didier Surdez et al.

Summary: The study reveals that STAG2-LOF fine-tunes the activity of an oncogenic transcription factor by altering anchored CTCF loop extrusion and enhancer mechanisms, thereby affecting the invasive behavior of Ewing sarcoma cells.

CANCER CELL (2021)

Add to Collection

Article Pathology

Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour

Tatiana Georgiesh et al.

Summary: This study found that NAB2-STAT6 fusion variants are associated with distinct clinicopathological and molecular characteristics in solitary fibrous tumour patients, and have prognostic significance in extrameningeal SFT.

PATHOLOGY (2021)

Add to Collection

Article Oncology

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. Gronchi et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

S. J. Strauss et al.

Summary: The paragraph lists the names of various researchers, possibly in the author list of a research paper.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Bryan D. Smith et al.

Summary: Macrophages can play a role in various diseases, with focus on the importance of CSF1R. Targeted therapies against CSF1R, such as Vimseltinib, show promise in inhibiting tumor growth and bone degradation.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection

Article Pathology

Malignant Mesothelioma With EWSR1-ATF1 Fusion in Two Adolescent Male Patients

Hezhen Ren et al.

Summary: This article presents two pediatric cases of EWSR1-ATF1 translocation-associated malignant mesothelioma in the peritoneum and pericardium, both lacking a known exposure history. Microscopic examination revealed predominantly epithelioid morphology with positive immunohistochemistry results, and RNA sequencing confirmed EWSR1-ATF1 gene rearrangement in both cases.

PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2021)

Add to Collection

Article Oncology

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Peter Horak et al.

Summary: Comprehensive molecular analysis in rare cancers can lead to evidence-based management recommendations and significantly improved clinical outcomes, paving the way for future clinical trials and potentially improving access to experimental treatments for this underserved patient population.

CANCER DISCOVERY (2021)

Add to Collection

Review Oncology

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

Sebastian Bauer et al.

Summary: While traditional GIST treatments target specific kinase mutations, resistance to these therapies is common, leading to the development of next-generation TKIs with broader therapeutic options.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

The genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities

Christopher D. Steele et al.

SEMINARS IN CANCER BIOLOGY (2020)

Add to Collection

Article Oncology

Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing

Martee L. Hensley et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

William D. Tap et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma

Lisa Mirabello et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Andrea M. Gross et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial

Thomas Filleron et al.

BMC CANCER (2020)

Add to Collection

Article Immunology

CCND1Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors

Yu Chen et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas

Varun Monga et al.

CANCERS (2020)

Add to Collection

Article Pathology

Sarcoma and the 100,000 Genomes Project: our experience and changes to practice

Sophie C. Prendergast et al.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2020)

Add to Collection

Article Oncology

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Jean-Yves Blay et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Michael C Heinrich et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The nucleosome acidic patch and H2A ubiquitination underlie mSWI/SNF recruitment in synovial sarcoma

Matthew J. McBride et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

Add to Collection

Review Medicine, Research & Experimental

Sarcoma treatment in the era of molecular medicine

Thomas G. P. Grunewald et al.

EMBO MOLECULAR MEDICINE (2020)

Add to Collection

Article Oncology

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Mrinal Gounder et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Oncology

Prognostic significance of CTNNB1 mutation in recurrence of sporadic desmoid tumors

Lifang Guo et al.

Summary: Desmoid tumor (DT) is a rare, locally aggressive benign neoplasm with a high recurrence rate, often associated with CTNNB1 mutations. Among CTNNB1 mutations, the S45F mutation is a high-risk factor for recurrence of DT, while the T41A mutation and other mutations show no significant differences in recurrence rates.

FUTURE ONCOLOGY (2020)

Add to Collection

Article Genetics & Heredity

Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)

Kris G. Samsom et al.

BMC MEDICAL GENOMICS (2020)

Add to Collection

Review Oncology

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

G. D. Demetri et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

Changxia Shao et al.

JAMA NETWORK OPEN (2020)

Add to Collection

Review Oncology

Molecular targets and novel therapeutic avenues in soft-tissue sarcoma

A. Elkrief et al.

CURRENT ONCOLOGY (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The pathology of soft tissue sarcomas

Marta Sbaraglia et al.

RADIOLOGIA MEDICA (2019)

Add to Collection

Article Oncology

Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways

Christopher D. Steele et al.

CANCER CELL (2019)

Add to Collection

Article Oncology

Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database

S. Bonvalot et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1

Lehang Lin et al.

NUCLEIC ACIDS RESEARCH (2019)

Add to Collection

Article Oncology

The central nervous system tumor methylation classifier changes neurooncology practice for challenging brain tumor diagnoses and directly impacts patient care

Shirin Karimi et al.

CLINICAL EPIGENETICS (2019)

Add to Collection

Article Hematology

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Carlo Gambacorti-Passerini et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Review Oncology

Emerging Targeted and Immune-Based Therapies in Sarcoma

Seth M. Pollack et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Oncology

Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours

Armelle Dufresne et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Pathology

Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience

Bharat Rekhi et al.

ANNALS OF DIAGNOSTIC PATHOLOGY (2018)

Add to Collection

Article Pathology

Detection of GNAS mutations in intramuscular / cellular myxomas as diagnostic tool in the classification of myxoid soft tissue tumors

Sandra Sunitsch et al.

DIAGNOSTIC PATHOLOGY (2018)

Add to Collection

Review Oncology

NTRK fusion-positive cancers and TRK inhibitor therapy

Emiliano Cocco et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Review Engineering, Electrical & Electronic

Fluorescence in situ hybridization (FISH): History, limitations and what to expect from micro-scale FISH?

D. Huber et al.

MICRO AND NANO ENGINEERING (2018)

Add to Collection

Review Oncology

Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications

Zoltan Szucs et al.

FUTURE ONCOLOGY (2017)

Add to Collection

Article Oncology

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study

Yael P. Mosse et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial

Heikki Joensuu et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Oncology

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results Analysis of Phase 3 SWOG Intergroup Trial S0033

Michael C. Heinrich et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

Alexander J. Lazar et al.

CELL (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain

Gaylor Boulay et al.

CELL (2017)

Add to Collection

Article Medicine, General & Internal

Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report

Cai Yuan et al.

AMERICAN JOURNAL OF CASE REPORTS (2017)

Add to Collection

Meeting Abstract Oncology

Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses

Melissa Amber Burgess et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)

Xavier Garcia del Muro et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Guidelines for diagnostic next-generation sequencing

Gert Matthijs et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2016)

Add to Collection

Review Oncology

Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes

Fredrik Mertens et al.

GENES CHROMOSOMES & CANCER (2016)

Add to Collection

Article Oncology

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

E. Ben-Ami et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Review Cell Biology

Mesenchymal stem cells: From stem cells to sarcomas

Kwan Liang Lye et al.

CELL BIOLOGY INTERNATIONAL (2016)

Add to Collection

Article Oncology

Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study

Antoine Italiano et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Monogenic and polygenic determinants of sarcoma risk: an international genetic study

Mandy L. Ballinger et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Eva Dombi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Oncology

Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review

Mohamad Farid et al.

ONCOLOGIST (2016)

Add to Collection

Article Surgery

Epidemiology and Etiology of Sarcomas

Jane Y. C. Hui

SURGICAL CLINICS OF NORTH AMERICA (2016)

Add to Collection

Article Medicine, Research & Experimental

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

Jonathan D. Oliner et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)

Add to Collection

Article Oncology

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial

Mark A. Dickson et al.

JAMA ONCOLOGY (2016)

Add to Collection

Review Orthopedics

Diagnostic work up and recognition of primary bone tumours: a review

James Plant et al.

EFORT OPEN REVIEWS (2016)

Add to Collection

Article Oncology

Clinical Outcomes of Patients With Advanced Gastrointestinal Stromal Tumors: Safety and Efficacy in a Worldwide Treatment-Use Trial of Sunitinib

Peter Reichardt et al.

CANCER (2015)

Add to Collection

Review Oncology

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

Maria Schwaederle et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Is DOG1 Immunoreactivity Specific to Gastrointestinal Stromal Tumor?

William Swalchick et al.

CANCER CONTROL (2015)

Add to Collection

Review Oncology

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

Aria Vaishnavi et al.

CANCER DISCOVERY (2015)

Add to Collection

Article Pathology

Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics

Leona A. Doyle et al.

MODERN PATHOLOGY (2014)

Add to Collection

Article Biochemistry & Molecular Biology

PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations

A. I. Velghe et al.

ONCOGENE (2014)

Add to Collection

Article Oncology

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program

Attila Kollar et al.

CLINICAL SARCOMA RESEARCH (2014)

Add to Collection

Article Oncology

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Christian Tovar et al.

CANCER RESEARCH (2013)

Add to Collection

Article Oncology

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Mark A. Dickson et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri et al.

LANCET (2013)

Add to Collection

Article Oncology

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Yael P. Mosse et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Genetics & Heredity

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone

Sam Behjati et al.

NATURE GENETICS (2013)

Add to Collection

Article Oncology

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

Stephen X. Skapek et al.

PEDIATRIC BLOOD & CANCER (2013)

Add to Collection

Article Oncology

Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions

I. Ray-Coquard et al.

ANNALS OF ONCOLOGY (2012)

Add to Collection

Article Oncology

Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors

Michael C. Heinrich et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

Article Oncology

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

Philippe A. Cassier et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

Article Anatomy & Morphology

Sox10 and S100 in the Diagnosis of Soft-tissue Neoplasms

Jason R. Karamchandani et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)

Add to Collection

Review Oncology

The Epidemiology of Sarcoma

Zachary Burningham et al.

CLINICAL SARCOMA RESEARCH (2012)

Add to Collection

Article Pathology

MUC4 Is a Highly Sensitive and Specific Marker for Low-grade Fibromyxoid Sarcoma

Leona A. Doyle et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)

Add to Collection

Article Pathology

ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

Markku Miettinen et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)

Add to Collection

Article Oncology

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib

Silvia Stacchiotti et al.

INTERNATIONAL JOURNAL OF CANCER (2011)

Add to Collection

Article Oncology

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

M. Fernanda Amary et al.

JOURNAL OF PATHOLOGY (2011)

Add to Collection

Article Oncology

Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients

Delphine Kerob et al.

CLINICAL CANCER RESEARCH (2010)

Add to Collection

Article Biochemistry & Molecular Biology

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

Frederic Chibon et al.

NATURE MEDICINE (2010)

Add to Collection

Review Genetics & Heredity

APPLICATIONS OF NEXT-GENERATION SEQUENCING Sequencing technologies - the next generation

Michael L. Metzker

NATURE REVIEWS GENETICS (2010)

Add to Collection

Article Medicine, General & Internal

Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor

James E. Butrynski et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Review Pathology

Well-differentiated and dedifferentiated liposarcomas

Jean-Michel Coindre et al.

VIRCHOWS ARCHIV (2010)

Add to Collection

Article Oncology

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

S. George et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Pathology

Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts)

Wei-Lien Wang et al.

MODERN PATHOLOGY (2009)

Add to Collection

Review Oncology

PAX3-FOXO1 fusion gene in rhabdomyosarcoma

Corinne M. Linardic

CANCER LETTERS (2008)

Add to Collection

Article Oncology

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation

Barbara Dewaele et al.

CLINICAL CANCER RESEARCH (2008)

Add to Collection

Article Oncology

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases

Michael C. Heinrich et al.

CLINICAL CANCER RESEARCH (2008)

Add to Collection

Article Oncology

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Michael C. Heinrich et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Oncology

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

Michael C. Heinrich et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Oncology

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033

Charles D. Blanke et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Oncology

EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma

Cristina R. Antonescu et al.

GENES CHROMOSOMES & CANCER (2007)

Add to Collection

Article Gastroenterology & Hepatology

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

Ellen Weisberg et al.

GASTROENTEROLOGY (2006)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George D. Demetri et al.

LANCET (2006)

Add to Collection

Review Oncology

Genetic testing for hereditary cancers: The impact of gender on interest, uptake and ethical considerations

Lori d'Agincourt-Canning et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)

Add to Collection

Article Oncology

PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib

CL Corless et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Article Oncology

Imatinib mesylate: An attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans

VE Price et al.

PEDIATRIC BLOOD & CANCER (2005)

Add to Collection

Article Oncology

Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate

SV Labropoulos et al.

ANTI-CANCER DRUGS (2005)

Add to Collection

Article Oncology

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study B2225

GA McArthur et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Article Gastroenterology & Hepatology

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

M Debiec-Rychter et al.

GASTROENTEROLOGY (2005)

Add to Collection

Article Oncology

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

MC Heinrich et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

Add to Collection

Article Gastroenterology & Hepatology

Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors

S Hirota et al.

GASTROENTEROLOGY (2003)

Add to Collection

Article Oncology

Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case

A Gordon et al.

CANCER GENETICS AND CYTOGENETICS (2003)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

GD Demetri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

Add to Collection

Sarcoma care in the era of precision medicine

Related references

Export Citation

Share Paper